---
document_datetime: 2023-09-21 20:49:01
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/docetaxel-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: docetaxel-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.8076335
conversion_datetime: 2025-12-24 07:39:35.239625
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
EMA/628087/2020

## Docetaxel TEVA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0031              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 06/10/2020                          |                                             | SmPC and PL                      |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions

are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | the MAH                                                                                                                                                                                                                                                                                                                                                                     |            |            | authorised                    |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------|
| IB/0030   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                | 08/04/2020 | 28/04/2020 | SmPC and PL                   |
| IB/0029   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                | 25/06/2019 | 28/04/2020 | SmPC, Labelling and PL longer |
| IB/0028   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product                                                                                                        | 25/06/2018 | no         | SmPC, Labelling and PL        |
| IB/0027/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a Medicinal | 16/01/2018 |            | SmPC and PL                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                      | authorised                                  |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| IB/0026/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by product | 05/10/2017 SmPC, Labelling and PL no longer |
| IB/0024/G | the MAH This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier Medicinal                                                                                                                                                                                                                                                                                                                                                              | 03/08/2016 n/a                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished   | product    | no         | longer authorised   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| IA/0023 | product - Other changes to a test procedure (including replacement or addition) A.7 - Administrative change - Deletion of manufacturing sites Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/04/2016 | 16/02/2017 | Annex II and PL     |
| IB/0022 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/02/2016 | 16/02/2017 | SmPC, Labelling and |

<div style=\"page-break-after: always\"></div>

|                    | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                |                    |               | PL                     | authorised                        |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|------------------------|-----------------------------------|
| T/0021             | Transfer of Marketing Authorisation                                                                                                                                                                                                                          | 04/11/2014         | 21/11/2014    | SmPC, Labelling and    |                                   |
| PSUSA/1152/ 201311 | Periodic Safety Update EU Single assessment - docetaxel                                                                                                                                                                                                      | 25/09/2014         | n/a           |                        | PRAC Recommendation - maintenance |
| IB/0020            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 20/08/2014         | 21/11/2014 no | SmPC longer            |                                   |
| R/0013             | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 22/05/2014 product | 14/07/2014    | SmPC, Labelling and PL |                                   |
| IB/0018            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                         | 05/06/2014         | n/a           |                        |                                   |
| IB/0017            | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process Medicinal                                                                                                               | 05/06/2014         | n/a           |                        |                                   |
| IB/0016            | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including                                                                                                                                                        | 03/06/2014         | n/a           |                        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014   | Update of section 4.4 and 4.5 of the SmPC in order to add a warning and update the safety information on interactions with CYP3A4 inhibitors further to the PRAC assessment of a signal. In addition, some inconsistencies have been rectified on the number and grade of alopecia adverse reactions in section 4.8 of the SmPC. Furthermore, the contact details for the Maltese local representative have been updated. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH 19/03/2014 03/06/2014 SmPC and PL no longer authorised |
| IB/0012/G | This was an application for a group of variations. To update section 4.4 to add warning on cystoid macular oedema based on the results of safety cumulative reviews conducted by the innovator's MAH and section 4.8 of the SmPC to include cystoid macular oedema and hyponatraemia in the list of adverse reactions following assessment by the CHMP for the originator product Taxotere. The Package Leaflet is updated accordingly. In addition the product information has been brought in line with the latest QRD version 9.0. Finally, the contact details for the new Member State Croatia have been added to the list of local representatives in the Package Leaflet 10/10/2013 03/06/2014 SmPC and PL Medicinal product           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | and the contact details for Hungary have been updated. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009 | Update of the SmPC for Docetaxel Teva following assessment of the same changes for the reference product, Taxotere. Sections 4.4 and 4.8 of the SmPC are updated in order to add a warning related to respiratory disorders and to include interstitial pneumonitis, interstitial lung disease and pulmonary fibrosis as new adverse reactions observed the post- marketing setting following a relevant cumulative review of the originator product's safety database. The Package Leaflet is updated accordingly. The MAH has also taken the opportunity to update the MAH contact details in section 6 of the Package Leaflet. In addition, minor linguistic amendments were carried out in the CS, FI, RO annexes. C.I.2.a - Change in the SPC, Labelling or PL of a 12/06/2013 03/06/2014 Medicinal product no |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| IAIN/0010 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/05/2013 n/a               |
| IAIN/0008 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/06/2012 11/09/2012 longer |
| IB/0007   | Update of SmPC section 4.5 regarding interaction between docetaxel and ritonavir as well as update of SmPC section 4.8 regarding the risk of renal dysfunction, respiratory disorders, persisting alopecia and the frequency for leukaemia/MDS in the post- marketing section in accordance with the update for the reference product. The package leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the PI in line with QRD version 8 as well as to introduce corrections to SmPC section 4.8 as well as section 5.3 of the 80 mg strength in line with the reference poduct. Furthermore, the contact details of the LoLR in the package leaflet have been updated. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Medicinal product | 10/05/2012 11/09/2012 no     |

<div style=\"page-break-after: always\"></div>

| IB/0006   | Update of SmPC sections 4.4, 4.8 and 5.1 following the final results of study TAX 316 in accordance with the update for the reference product Taxotere. In addition, the MAH took the opportunity to update the list of local representatives. Additionally, corrections have been introduced in the following languages: BG, CS, DE, FI, PT and RO. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   | 03/02/2012   | 11/09/2012    | SmPC and PL            | authorised                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | To add a new therapeutic indication following the same changes for the reference product Taxotere (II- 90 adopted in May 2010). In addition, few formatting changes have been carried out and the DDPS version number has been removed from Annex II. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH product                                                                                          | 08/02/2011   | n/a no longer | SmPC, Annex II and PL  | To add a new therapeutic indication in order to reflect the changes to the innovator product Taxotere (II-90 adopted in May 2010). Few formatting changes have been carried out. |
| II/0002/G | This was an application for a group of variations. Changes relating to the Docetaxel Teva concentrate including: - change in the formulation of the Docetaxel Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/07/2010   | 26/08/2010    | SmPC, Labelling and PL |                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | life based on extrapolation of stability data not in accordance with ICH guidelines B.II.c.1.f - Change in the specification parameters and/or limits of an excipient - Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a safety or quality issue   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001/G | This was an application for a group of variations. 22/07/2010 26/08/2010                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.f.1.b.4 - Stability of FP - Extension of the shelf life of the finished product - Extension of the shelf- life based on extrapolation of stability data not in accordance with ICH guidelines   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003/G | This was an application for a group of variations. 22/07/2010                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | relates to all other pharmaceutical forms manufactured by complex manufacturing processes   |
|-----------|---------------------------------------------------------------------------------------------|
| IA/0004/G | This was an application for a group of variations. 27/05/2010                               |

<!-- image -->